AIM ImmunoTech Rights Offering Shortfall
Analysis based on 6 articles · First reported Feb 11, 2026 · Last updated Mar 07, 2026
The market is negatively impacted by AIM ImmunoTech's rights offering, as the company only raised $1.8 million, significantly less than the anticipated $12 million. This shortfall in capital raising could lead to concerns about AIM ImmunoTech's financial health and future development plans.
AIM ImmunoTech commenced a rights offering in February 2026 to raise capital, initially aiming for $12 million. The offering involved distributing subscription rights to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants. The terms of the offering were updated on February 27, 2026, adjusting the conversion and exercise prices. The offering expired on March 3, 2026, with preliminary results announced on March 4, 2026, indicating total subscriptions of approximately $1.8 million. The closing of the rights offering occurred on March 6, 2026, confirming the $1.8 million raised. Maxim Group LLC acted as the dealer-manager, and Broadridge Financial Solutions, LLC was the subscription agent. The United States — United States Securities and Exchange Commission declared the registration statement effective on February 10, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard